个人信息
教师姓名:邓旭

学位:博士学位

学历:博士研究生毕业

职称:教授

所在单位:湘雅药学院

学术荣誉: 曾获荣誉:
云南省自然科学二等奖
中国科学院研究生院“朱李月华优秀博士生奖”
个人简介

     一、个人简介

邓旭,湖北大悟人,教授,博士生导师,主要研究兴趣是基于中药来源活性天然产物的抗呼吸道感染新药创制研究。曾入选湖南省杰青、湖南省卫生健康高层次人才等;主持和承担国家重点研发计划子课题、国家自然科学基金面上项目、科技部高端外国专家引进计划、湖南省重点研发计划等各类纵向课题10余项,以及企业产学研合作项目多项;在国际期刊发表高水平研究论文60余篇,其中以第一作者/通讯作者在Nature Comm., Angew. Chem. Int. Ed., J. Med. Chem.等期刊发表SCI论文30余篇,总被引1500余次 (Google Scholar)H指数24;以主要发明人申请专利20余项(包括PCT专利1项),其中12项已获授权。此外,邓旭博士还应邀担任Natural Products & Bioprospecting青年编委、国家自然科学基金委/广东省/湖南省各类科技计划项目评审专家,以及Adv. Sci., Theranostics, J. Med. Chem.30余种学术期刊特邀审稿人,并荣获2020年度德国Thieme Chemistry Journals Award国际学术奖和2023年度云南省自然科学二等奖1项。

热忱欢迎热爱天然药物化学、有志于创新天然药物研究的本科生、硕士生、博士生与博士后加入团队!

通讯地址: 长沙市岳麓区桐梓坡路172号湘雅医学院药学楼C608

E-mails: dengxu3817@csu.edu.cn

个人网页 https://faculty.csu.edu.cn/dengxu/zh_CN/index.htm

ORCIDhttps://orcid.org/0000-0001-7683-1626

 

二、研究领域

1. 基于中药来源活性天然产物的抗呼吸道感染新药创制研究;

2. 基于新颖结构活性天然产物的化学生物学研究;

3. 活性天然产物合成(二萜、生物碱等)。

 

三、工作及学习经历

(一)教育经历

2007/9 - 2012/6,中国科学院昆明植物研究所,药物化学,硕博连读,导师:赵勤实研究员

2003/9 - 2007/6,中南大学,药学,理学学士

(二)工作经历

2025/9 – 至今,中南大学,湘雅药学院,教授,博士生导师

2018/9 – 2025/9,中南大学,湘雅药学院,副教授,博士生导师

2018/12 – 2019/12,加拿大女王大学,访问学者(合作导师:P. Andrew Evans教授)

2016/9 – 2018/9,中南大学,湘雅药学院,讲师,硕士生导师

2014/9 - 2016/08,武汉大学,化学与分子科学学院,博士后(合作导师:张绪穆教授)

2012/7 - 2014/8,中国科学院昆明植物研究所,植物化学与西部植物资源持续利用国家重点实验室,助理研究员

 

、获奖及荣誉

科研获奖:

1. 德国Thieme Chemistry Journals Award2020

2. 2023年度云南省自然科学二等奖

教学获奖:

1. 中南大学研究生教学成果二等奖(2022年度,排2

2. 中南大学20172023年度教学质量优秀奖

3. 中南大学优秀班导师(2018年度)

 

、近年来主持的代表性课题(负责人)

1. 国家重点研发计划项目(参与,子课题负责人,2023YFC2606500),2024/01-2026/12

2. 国家自然科学基金面上项目(22377151),2024.01-2027.12

3. 科技部高端外国专家引进计划项目(G20200018017G2021161003LG2023161004L),2020.01-2024.12

4. 湖南省杰出青年基金(2023JJ10083),2023.1-2025.12

5. 湖南省重点研发计划项目(2021WK2005),2021.09-2023.08

6. 国家自然科学基金青年项目(21302193),2014.01-2016.12

7. 湖南省自然科学基金面上项目(2021JJ30894),2021.01-2023.12

 

5年的代表性专利(限10项)

(1) 发明人:邓旭,曹东升,王庆,周应军,王森林,范金宝;《一种吲哚啉类化合物的制备方法》,授权公告日:2023-10-3;授权号:ZL2022106157434

(2) 发明人:曹东升,邓旭,田欢,吴炎,王庆,范金宝;《一种吲哚二聚体类化合物的制备方法》,授权公告日:2022-06-29;授权号:ZL202210646470.X

(3) 发明人:邓旭,周应军,杨舒婷,范金宝,宁帅,徐嘉浩,曾光尧;《独角金内酯衍生物在制备线粒体自噬抑制剂中的应用》,授权公告日:2022-08-04;专利号:ZL202110893493.6

(4) 发明人:邓旭,周应军,曹伟,刘婷婷,杨舒婷,曾光尧;《Icetexane型松香烷二萜在制备结直肠癌治疗药物中的应用》,授权公告日:2022-04-01;专利号:ZL202011641683.0

(5) 发明人:邓旭,周应军,曹伟,刘婷婷,杨舒婷,曾光尧;《一种Icetexane型松香烷二萜的制备方法》,授权公告日:2022-04-01;专利号: CN202011641565.X

(6) 发明人:邓旭,周应军,马锦锦,李元建,曾光尧;《吴茱萸次碱-NO供体偶联物及其应用》,授权公告日:2018-11-06;专利号:ZL201811310581.3

(7) 发明人:邓旭,刘婷婷,周应军,严林洋,曹东升,曾光尧;《一种甲异靛衍生物的制备方法与应用》,授权公告日:2023-08-13;专利号:ZL202210587486.8

(8) 发明人:邓旭,刘嫣芸,李正澳,王森林,周宇筝,周应军,夏赞贤,曾光尧;《DNJ 衍生物、药物组合物及其应用》,授权公告日:2025-10-10;专利号:ZL202510035267.2.

(9). 发明人:李晓晖,邓旭,殷明慧,冯雪祥,王森林、李莹,周应军;DNJ及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用;专利号:ZL202210433992.1.

(10) 发明人:周应军,曹伟,邓旭,李元建,曾光尧;《鼠尾草酸或其衍生物在制备治疗糖尿病并发症药物中的应用》,授权公告日:2021-07-20;专利号: ZL202010716007.9

 

近年来发表的代表性科研论文

(1) Tingting Liu#, Xingyue Chen#, Shah Nawaz Khan, Xiaoxu Li, Bo Kong, Yingjun Zhou, Yangyan Li, Yuhua Ge, Gang Chen*, Xu Deng*; Phytohormone Strigolactams Overcomes Oxaliplatin Resistance in Colorectal Cancer by Blocking the Late-Stage Autophagy to Tip the Metabolic Balance toward Ferroptosis. Journal of Medicinal Chemistry, 2025, 68 (22), 24546-24559.

(2). Ling-Fang Peng#, Kai-Qiang Fan #, Yu-Xing Zhou#, Tao Feng, Peng Zhan, Ying-Jun Zhou*, Xu Deng*; A Dehydrogenative Diels-Alder/Aromatization Sequence to Access 6/6/6/6/5 Pentacyclic Steroids: Their Anti-inflammatory Activities. Organic Letters, 2025, 27(6), 1335-1339.

(3). Yan-Yun Liu#, Zheng-Ao Li#, Yu-Zheng Zhou #, Sen-Lin Wang, Zong-Peng Chen, Si-Xu Liu, Peng Zhan, Ying-Jun Zhou, Zan-Xian Xia*, Xu Deng*; TCM theory-inspired discovery of DNJ-flavonoid conjugates as broad-spectrum anti-SARS-CoV-2 agents by primarily targeting ER-associated glycoprotein folding process. European Journal of Medicinal Chemistry, 2025, 290: 117582.

(4). Fan Zhou#, Dazhou Shi#, Baohu Li, Mei Wang, Shujing Xu*, Jinfei Yang*, Xu Deng*, Peng Zhan*; Antiviral strategies based on targeted protein degradation: an overview of the literature and future outlook. European Journal of Medicinal Chemistry, 2026, 301: 118208.

(5). Qiantong Liu#, Yanyun Liu#, Tingting Liu, Jinbao Fan, Zanxian Xia, Yingjun Zhou, Xu Deng*; Expanding horizons of iminosugars as broad-spectrum antivirals: mechanism, efficacy and novel developments. Natural Products & Bioprospecting, 2024, 14, 55.

(6). Tingting Liu#, Qing Wang #, Yuxin Zhou, Baixin Ye, Tingting Liu, Linyang Yan, Jinbao Fan, Yingjun Zhou, Zanxian Xia*, Xu Deng*; Discovery of a meisoindigo-derived PROTAC as the ATM degrader: revolutionizing colorectal cancer therapy via synthetic lethality with ATR inhibitors. Journal of Medicinal Chemistry, 2024, 67 (9), 7620-7634.

7Qingtian Gao#, Sixu Liu#, Yuzheng Zhou, Jinbao Fan, Shufen Ke, Yuqing Zhou, Kaiqiang Fan, Yuxuan Wang, Yingjun Zhou, Zanxian Xia*, Xu Deng*, Discovery of Meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19. European Journal of Medicinal Chemistry, 2024. 2024, 273, 11648.

8Jin-Bao Fan#, Liyang Shi#, Qing Wang, Yan Zeng, Wei Cao, Guangyao Zeng, Yingjun Zhou, Xu Deng*, RhI-Catalyzed Cycloisomerization Reactions of 1, 7-Enynes To Access Cage-Like Tricyclo [3.2. 2.06, 8] nonenes. Synthesis, 2024. 56, 2918-2924.

9Aroona Razzaq, Cyrollah Disoma, Yuzheng Zhou, Siyi Tao, Zongpeng Chen, Sixu Liu, Rong Zheng, Yongxing Zhang, Yujie Liao, Xuan Chen, Sijie Liu, Zijun Dong, Liangtao Xu, Xu Deng*, Shanni Li*, Zanxian Xia*, Targeting epidermal growth factor receptor signalling pathway: A promising therapeutic option for COVID‐19. Reviews in Medical Virology, 2024. 34, e2500.

10Moude Liu#, Qin Tang#, Qing Wang, Weixi Xie, Jinbao Fan, Siyuan Tang, Wei Liu, Yingjun Zhou*, Xu Deng*, Rapid access to icetexane diterpenes: their protective effects against lipopolysaccharides-induced acute lung injury via PI3K/AKT/NF-B axis in macrophages. European Journal of Medicinal Chemistry, 2023, 260, 115769.  

(11). Yan Wu#, Moude Liu#, Qing Wang, Huan Tian, Jinbao Fan, Yingjun Zhou, Yajing Wang*, Xu Deng*; Divergent Synthesis of Bis(indolyl) methanes via FeIII catalyzed Regioselective Dehydrogenative Coupling Reactions: A Biomimetic Approach to 6,6’-bis-(debromo)-gelliusine F. Organic & Biomolecular Chemistry, 2023, 21, 639-643.

(12). Shuting Yang#, Jinbao Fan#, Tingting Liu#, Shuai Ning, Jiahao Xu, Yingjun Zhou*, Xu Deng*; Development of strigolactones as novel autophagy/mitophagy inhibitors against colorectal cancer cells by blocking the autophagosome-lysosome fusion. Journal of Medicinal Chemistry, 2022, 65, 9706-9713.

(13). Qing Wang, Senlin Wang, Jinbao Fan, Guangyao Zeng, Yingjun Zhou*, Xu Deng*; Acid-promoted intra- and intermolecular [2+2] cycloaddition of indoles with aryl alkynes to access cyclobutene-based indolines. Chemical Communications, 2022, 58, 9270-9273.

(14).  Xu Deng#, Suling Huang#, Jian Ren, Zhenghong Pan, Yu Shen, Haofeng Zhou, Zhili Zuo*, Ying Leng*, Qinshi Zhao*; Development and structure-activity relationships of tanshinones as selective 11β-hydroxysteroid dehydrogenase 1 inhibitors. Natural Product & Bioprospecting, 2022, 12. 36.

(15). Wei Cao#, Tingting Liu#, Shuting Yang, Moude Liu, Zhenghong Pan, Yingjun Zhou*, Xu Deng*; Efficient synthesis of icetexane diterpenes and apoptosis inducing effect by upregulating Bip-ATF4-CHOP axis in colorectal cells. Journal of Natural Products, 2021, 84, 2012-2019.

16Xu Deng#, Li-Yang Shi#, Jia-ling Lan#, Yu-Qing Guan, Xiao-yong Zhang, Hui Lv*, Lung-Wa Chung*, Xu-mu Zhang*; Enantioselective rhodium-catalyzed cycloisomerization of 1,6-allenynes to access 5/6-fused bicycle[4.3.0]nonadienes, Nature Communications, 2019, 10, 949-959.

17Wei Cao, Jin-Bao Fan, Ling-Yang Yan, Guang-Yao Zeng, Jin-Jin Ma, Ya-Jing Wang, Ying-Jun Zhou*, Xu Deng*, Divergent reactivity in CuII-catalyzed oxidative coupling between indole/tryptamine derivatives and β-arylacrylic acids, Organic Letters, 2019, 21, 9506-9511.

18Jin-jin Ma#, Lan Chen#, Jin-bao Fan, Wei Cao, Guang-yao Zeng, Ya-jing Wang, Yuan-jian Li,  Ying-jun Zhou*, Xu Deng*; Dual-targeting rutaecarpine-NO donor hybrids as novel anti-hypertensive agents by promoting release of CGRP, European Journal of Medicinal Chemistry, 2019, 168, 146-153.

19Xiaofeng Chen#, Jinbao Fan#, Guangyao Zeng, Jinjin Ma, Chenxi Wang, Yajing Wang, Yingjun Zhou*, Xu Deng*; Access to 3a-Benzoylmethyl Pyrrolidino[2,3-b]indolines via CuII-Catalyzed Radical Annulation/C3-Functionalization Sequence, The Journal of Organic Chemistry, 2018, 83, 8322-8330.

20Shuai Ning#, Lei Zhang#, Jin-jin Ma, Lan Chen, Guangyao Zeng, Yingjun Zhou, Xiaoli Guo*, Xu Deng*, Modular and scalable synthesis of nematode pheromone ascarosides: implications in eliciting plant defense, Organic & Biomolecular Chemistry, 2020, 18 (26), 4956-4961.


论文成果
当前位置 : 中文主页 >> 论文成果

Development of novel conformation-constrained cytotoxic derivatives of cheliensisin A by embedment of small heterocycles


点击次数:

发表刊物:European Journal of Medicinal Chemistry

合写作者:Qin-Shi Zhao*, Zhu-Jun Yao*, Yan Li, Li-Yan Peng, Yu Zhao, Jia Su, Xu Deng

论文类型:基础研究

学科门类:药学

文献类型:J

卷号:46

页面范围:4238-4244

是否译文:

发表时间:2011-09-30


上一条: Exploring of drug leads from diversity-oriented Michael-acceptor library derived from natural products

下一条: Cheliesisin A inhibits EGF-induced cell transformation with stablization of p53 protein via a hydrogen peroxide/Chk1 dependent axis


手机版

同专业博导  同专业硕导

访问量:

中南大学版权所有 湘ICP备05005659号-1

最后更新时间:..